The DEA's proposal to reclassify marijuana as a Schedule III drug is a significant regulatory shift that directly impacts the cannabis industry, particularly companies and ETFs like MSOS that are focused on the U.S. cannabis market. The surge in MSOS's price reflects investor optimism about the easing of research restrictions and enforcement practices, which could lead to expanded market opportunities and increased profitability for companies within the ETF's portfolio. The high relevance, importance, and confidence scores are based on the direct mention of MSOS and the clear positive market reaction to the news.